Education
About Us
Working with TipRanks
Follow Us
Skye Bioscience (SKYE)
NASDAQ:SKYE
SKYE Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.14 - $5.96
Previous CloseN/A
Volume18.00K
Average Volume (3M)321.34K
Market Cap
$120.54M
Enterprise Value$117.56M
Total Cash (Recent Filing)$48.59M
Total Debt (Recent Filing)$367.54K
Price to Earnings (P/E)―
Beta1.97
Next Earnings
Nov 06, 2025EPS Estimate
-0.3Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.44
Shares Outstanding30,988,420
10 Day Avg. Volume368,321
30 Day Avg. Volume321,342
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.98
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-194.07
Enterprise Value/Ebitda-2.83
Forecast
1Y Price Target
$15.20Price Target Upside324.58% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
Bulls Say, Bears Say
Bulls Say
Clinical TrialsThe upcoming Phase IIa CBeyond 26-week top-line data of nimacimab is expected to show significant weight loss in obesity and overweight patients.
Market PotentialGiven the sizable addressable market in the obesity space, even modest penetration could translate to significant upside for investors.
Safety ProfilePhase Ib results show benign gastrointestinal tolerability and absence of significant neuropsychiatric adverse events for nimacimab in metabolic-associated steatotic liver disease.
Bears Say
Clinical Trial RisksThe discussion of Phase Ib results is relevant given the potential safety implications for the upcoming Phase IIa CBeyond 26-week top-line data.
Safety ConcernsThe frequency of neuropsychiatric events will be closely monitored, and any occurrence of these events would likely be viewed as too many.
Skye Bioscience News
SKYE FAQ
What was Skye Bioscience’s price range in the past 12 months?
Skye Bioscience lowest stock price was $1.14 and its highest was $5.96 in the past 12 months.
What is Skye Bioscience’s market cap?
Skye Bioscience’s market cap is $120.54M.
When is Skye Bioscience’s upcoming earnings report date?
Skye Bioscience’s upcoming earnings report date is Nov 06, 2025 which is in 41 days.
How were Skye Bioscience’s earnings last quarter?
Skye Bioscience released its earnings results on Aug 07, 2025. The company reported -$0.44 earnings per share for the quarter, missing the consensus estimate of -$0.32 by -$0.12.
Is Skye Bioscience overvalued?
According to Wall Street analysts Skye Bioscience’s price is currently Undervalued.
Does Skye Bioscience pay dividends?
Skye Bioscience does not currently pay dividends.
What is Skye Bioscience’s EPS estimate?
Skye Bioscience’s EPS estimate is -0.3.
How many shares outstanding does Skye Bioscience have?
Skye Bioscience has 30,988,420 shares outstanding.
What happened to Skye Bioscience’s price movement after its last earnings report?
Skye Bioscience reported an EPS of -$0.44 in its last earnings report, missing expectations of -$0.32. Following the earnings report the stock price went down -0.845%.
Which hedge fund is a major shareholder of Skye Bioscience?
Currently, no hedge funds are holding shares in SKYE
Skye Bioscience Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$15.20 (324.58% Upside)
$15.20 (324.58% Upside)
Blogger Sentiment
Bullish
SKYE Sentiment 100%
Sector Average 72%
Sector Average 72%
Insider Transactions
Sold Shares
Worth $1.6M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▲ 0.4%
Last 30 Days ▼ 3.5%
Last 30 Days ▼ 3.5%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
5.73%
12-Months-Change
Fundamentals
Return on Equity
-72.75%
Trailing 12-Months
Asset Growth
-40.22%
Trailing 12-Months
Company Description
Skye Bioscience
Skye Bioscience, Inc., a biopharmaceutical company, discovers, develops, and commercializes cannabinoid-based molecules for the treatment of infectious diseases. The company's lead product candidate is SBI-100, which is in Phase I trials for the treatment of glaucoma and ocular hypertension. It is also developing SBI-200 that is in preclinical trials to treat and manage various eye diseases, including uveitis, dry eye syndrome, macular degeneration and diabetic retinopathy. The company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc. in January 2021. Skye Bioscience, Inc. was founded in 2012 and is headquartered in San Diego, California.
SKYE Company Deck
SKYE Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call presented a balanced view of Skye Bioscience's progress. While the company showcased significant advancements in its clinical trials and financial stability, it also faced challenges with increased R&D expenses and a substantial net loss. The strategic developments and promising preclinical data are positive highlights, but the enrollment challenges in the extension study indicate areas needing attention.View all SKYE earnings summariesSKYE Stock 12 Month Forecast
Average Price Target
$15.20
▲(324.58% Upside)
Technical Analysis
Alterity Therapeutics
―
Actinium Pharmaceuticals
―
Mersana Therapeutics
―
Celularity
―
OnKure Therapeutics
―
Ownership Overview
66.72% Insiders
4.91% Mutual Funds
0.95% Other Institutional Investors
23.69% Public Companies and Individual Investors